What is the appropriate evaluation and management for a patient presenting with platinum disease (allergic or toxic reaction to a platinum‑containing substance)?

Management of Platinum Drug Hypersensitivity Reactions

For patients presenting with platinum drug reactions, immediately stop the infusion and administer antihistamines; for severe reactions involving blood pressure changes, dyspnea, or widespread urticaria, permanently discontinue the drug and consult an allergist before any rechallenge—never reuse the drug after anaphylaxis. 1

Immediate Recognition and Classification

Platinum drug reactions manifest in two distinct patterns that require different management approaches:

• Infusion reactions present with milder symptoms (flushing, rash, chills) that resolve quickly after stopping the infusion, though these can progress to severe reactions with re-exposure 1
• True allergic reactions cause persistent symptoms including shortness of breath, chest pain, tachycardia, hives, blood pressure changes, bronchospasm, and potential cardiovascular collapse that persist after stopping the infusion 1
• Carboplatin causes hypersensitivity reactions in 16% of patients, while cisplatin affects 5-20% and oxaliplatin up to 24% 1

Timing and High-Risk Scenarios

The peak incidence of carboplatin hypersensitivity occurs at the 8th or 9th exposure, typically during the second or third cycle of retreatment after disease recurrence. 1, 2

Critical risk factors include:

• Reintroduction after a period of no exposure following multiple prior cycles 1
• Retreatment interval exceeding 2 years increases hypersensitivity risk 1, 2
• Patients receiving their 8th carboplatin course require particular caution 1, 2
• IV administration carries higher risk than oral or intraperitoneal routes 1
• History of allergies to other drugs or previous platinum reactions 1

Acute Management Protocol

For First Exposure (Platinum-Naive Patients)

• Decrease the infusion rate immediately 1
• Symptoms typically resolve quickly after stopping infusion 1
• Administer antihistamine (diphenhydramine or hydroxyzine) 1
• If staff agree and vital signs remain stable, rechallenge with platinum drug 1
• Premedicate with antihistamine, corticosteroids, and H2 blockers (cimetidine or famotidine) 1
• Consider allergist consultation if possible 1

For Second or Further Exposure

• Administer antihistamine immediately to treat symptoms 1
• Add corticosteroid ± intramuscular epinephrine if symptoms do not quickly resolve 1
• Do not rechallenge or readminister drug until evaluated by allergist or specialist 1
• Patient becomes a candidate for desensitization protocols with each subsequent infusion 1

For Severe Reactions

For reactions involving blood pressure changes, dyspnea, tachycardia, widespread urticaria, or hypoxia, consult an allergist before any rechallenge attempt. 1

• Stop infusion immediately 1
• Administer aggressive symptomatic therapy including corticosteroids and epinephrine 1
• Patients who had mild reactions may develop more serious reactions even with slow platinum infusion 1
• Desensitization must be managed by a physician with expertise and experience in platinum desensitization 1

For Life-Threatening Anaphylaxis

The implicated platinum drug should never be used again after anaphylaxis. 1

• Anaphylaxis presents with acute onset, generalized hives, respiratory compromise, severe hypotension, and gastrointestinal symptoms 1
• Follow standard ACLS resuscitation procedures in acute cardiopulmonary arrest 1
• This is an absolute contraindication to future use of that specific platinum agent 1

Diagnostic Evaluation: Skin Testing

Consider allergist consultation and skin testing for patients who experienced a platinum reaction, as skin testing helps risk-stratify patients and guide desensitization protocols. 1

Carboplatin Skin Testing Protocol

• Step 1: 10 mg/mL (skin prick) 1
• Step 2: 0.01 mg/mL (intradermal) 1
• Step 3: 0.1 mg/mL (intradermal) 1
• Step 4: 1 mg/mL (intradermal) 1
• Note: Local skin necrosis has been reported with full 10 mg/mL concentration 1

Cisplatin Skin Testing Protocol

• Step 1: 1 mg/mL (skin prick) 1
• Step 2: 0.01 mg/mL (intradermal) 1
• Step 3: 0.1 mg/mL (intradermal) 1
• Step 4: 1 mg/mL (intradermal) 1

Oxaliplatin Skin Testing Protocol

• Step 1: 5 mg/mL (skin prick) 1
• Step 2: 0.05 mg/mL (intradermal) 1
• Step 3: 0.5 mg/mL (intradermal) 1
• Step 4: 5 mg/mL (intradermal) 1

Important caveat: The false-negative rate of carboplatin skin testing is as high as 8-8.5%, meaning some patients with negative skin tests will still develop hypersensitivity reactions on re-exposure. 1

• Skin testing has high sensitivity and specificity for platinum drugs and is critical to guide management 3
• Skin testing can provide reassurance and enable subsequent slowed infusion rates 1
• Severity of initial hypersensitivity reaction and skin testing results assist in risk stratification 1

Desensitization Protocols

If platinum therapy remains clinically necessary after a hypersensitivity reaction, desensitization is the only safe method to continue treatment, but it must be performed with each subsequent infusion. 1, 4

Key principles:

• Desensitization should be managed by physicians with expertise and experience in platinum desensitization 1
• Referral to an academic center with desensitization expertise is preferred 1
• Patients must be desensitized with each infusion if they previously had a drug reaction 1
• Even if symptoms resolved, patients should be desensitized before resuming chemotherapy 1
• Great caution should be undertaken if desensitization is pursued after even mild platinum reactions 1

Cross-Reactivity Between Platinum Agents

• Varying reports exist of cross-reactivity between platinum agents 1
• The lowest cross-reactivity occurs between oxaliplatin and cisplatin 1
• Skin testing identified cross-reactivity to another platinum compound in 33% of patients with positive tests 5
• If switching platinum agents, skin testing to alternative agents can guide selection 5

Mandatory Preparation and Prevention

Every treatment area must have appropriate emergency equipment available, and all clinicians and nursing staff must be prepared for drug reactions with every platinum infusion. 1

Essential preparedness measures:

• Patients and families must be counseled about the possibility of drug reactions and signs/symptoms to report, especially after leaving the clinic 1
• Standing orders should be written for immediate intervention in case of severe drug reactions 1
• Medical staff must know how to manage hypersensitivity reactions 1
• Emergency equipment must be immediately available in case of allergic reactions 1
• Many institutions have nursing policies stipulating how to reinfuse drugs after prior infusion reactions 1

Critical Pitfalls to Avoid

• Never assume premedication with corticosteroids and H1-antihistamines will prevent recurrent hypersensitivity reactions or anaphylaxis—it does not 1
• Never slowly reinfuse platinum drugs to patients with prior mild reactions without allergist consultation—mild reactions can progress to severe reactions with re-exposure 1
• Never confuse slow infusion with desensitization—these are distinct processes with different safety profiles 1
• Never rechallenge patients who had very severe life-threatening reactions—this is absolutely contraindicated 1
• Reactions can occur days after infusion completion, not just during infusion, requiring extended patient education about delayed symptom reporting 1

Long-Term Monitoring Considerations

• Circulating platinum remains detectable for more than 10 years after treatment completion 2
• Patients require monitoring for myelosuppression, dehydration, electrolyte loss, and end-organ toxicities (renal, hepatic) after each cycle 1
• For cisplatin specifically, adequate IV fluids must be administered before and after each cycle to prevent renal toxicity 1, 2
• Patients often require outpatient IV fluids post-chemotherapy to prevent or treat dehydration 1